Drugs / AAV8hAAT(AVL)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06996756 | Feb 2025 → Apr 2028 expected | alpha 1-antitrypsin deficiency | Weill Medical College of Cornell University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AAV8hAAT(AVL) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06996756 ↗ |
| Route | Intravenous | “intravenous delivery of this gene therapy” NCT06996756 ↗ |